Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Molecular Membrane Biology|October 1, 1994
Conformation of the cytoplasmic domain of phospholamban by NMR and CDJ A Hubbard, L K MacLachlan, E Meenan, et al.
Molecular Therapy. Methods & Clinical Development|January 24, 2018
Nonclinical Safety Evaluation of scAAV8-<i>RLBP1</i> for Treatment of <i>RLBP1</i> Retinitis PigmentosaTimothy K MacLachlan, Mark N Milton, Oliver Turner, et al.
Analytical Biochemistry|December 1, 2001
A method for identification of inhibitors of the phosphorylation reactions of bacterial response regulator proteins using (31)P nuclear magnetic resonance spectroscopyJ A Hubbard, L K MacLachlan, P Johnson, et al.
Regulatory Toxicology and Pharmacology : RTP|November 21, 2020
Industry experiences with immune-mediated findings in biotherapeutic nonclinical toxicology studiesTimothy K MacLachlan, Sven Kronenberg, Nikki Marshall, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 2, 2010
Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degenerationTimothy K Maclachlan, Michael Lukason, Margaret Collins, et al.
Regulatory Toxicology and Pharmacology : RTP|March 22, 2017
Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeuticsChristina L Zuch de Zafra, Vito G Sasseville, Steven Matsumoto, et al.
Regulatory Toxicology and Pharmacology : RTP|January 24, 2021
Classic and evolving approaches to evaluating cross reactivity of mAb and mAb-like molecules - A survey of industry 2008-2019Timothy K MacLachlan, Shari Price, Joy Cavagnaro, et al.
Toxicologic Pathology|October 8, 2010
Use of tissue cross-reactivity studies in the development of antibody-based biopharmaceuticals: history, experience, methodology, and future directionsMichael W Leach, Wendy G Halpern, Carol W Johnson, et al.
Pageof 5